Ibio Inc (NYSE MKT LLC:IBIO)

0.86
Delayed Data
As of Apr 17
 +0.0095 / +1.12%
Today’s Change
0.24
Today|||52-Week Range
3.48
+25.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$63.6M

Company Description

iBio, Inc. is a biotechnology company which focuses on commercializing its proprietary technology, the iBioLaunch platform, for biologics including vaccines and therapeutic proteins. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants and human blood plasma required by other systems, to produce important biologic pharmaceuticals. iBioModulator is a proprietary technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology including iBioLaunch. The company was founded on April 15, 1993 and is headquartered in Newark, DE.

Contact Information

iBio, Inc.
9 Innovation Way
Newark Delaware 19711
P:(302) 355-0650
Investor Relations:
(302) 355-2335

Employees

Shareholders

Other institutional31.04%
Individual stakeholders25.24%
Mutual fund holders2.58%

Top Executives

Robert B. KayExecutive Chairman & Chief Executive Officer
Robert L. ErwinPresident
Mark GiannoneChief Financial Officer
Terence E. RyanChief Scientific Officer
Douglas C. HicksVice President-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account